

# VERTEX PHARMACEUTICALS INC / MA

## FORM S-8

(Securities Registration: Employee Benefit Plan)

Filed 07/28/17

Address	50 NORTHERN AVENUE BOSTON, MA 02210
Telephone	6173416393
CIK	0000875320
Symbol	VRTX
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM S-8**

**REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

**VERTEX PHARMACEUTICALS INCORPORATED**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction of incorporation or  
organization)

**04-3039129**  
(I.R.S. Employer Identification Number)

**50 Northern Avenue  
Boston, Massachusetts 02210 (617) 341-6100**  
(Address of Principal Executive Offices)

**AMENDED AND RESTATED  
2013 STOCK AND OPTION PLAN**  
(Full Title of Plan)

**Jeffrey M. Leiden  
Chief Executive Officer  
Vertex Pharmaceuticals Incorporated  
50 Northern Avenue  
Boston, Massachusetts 02210  
(617) 341-6100**

(Name, address, and telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller reporting  
company)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

### CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price Per Share(2)	Proposed Maximum Aggregate Offering Price(2)	Amount of Registration Fee
Common Stock, \$0.01 par value	6,750,000	\$158.41	\$1,069,267,500	\$123,929

- (1) Consists of 6,750,000 additional shares of common stock, par value \$.01 per share, that may be issued under the Vertex Pharmaceuticals Incorporated Amended and Restated 2013 Stock and Option Plan (the "2013 Plan") pursuant to an amendment and restatement of the 2013 Plan that became effective June 8, 2017 (the "Effective Date"). The maximum number of shares that may be issued under the 2013 Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the 2013 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended, this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares that may be subject to grant or otherwise issuable after the operation of any such anti-dilution or other provisions.
- (2) Estimated solely for purposes of determining the registration fee pursuant to Rule 457(c) and (h) under the Securities Act of 1933, as amended, based on the average of the high and low sale prices of the Registrant's common stock as reported by The NASDAQ Global Select Market on July 27, 2017.

### **Statement of Incorporation by Reference**

This Registration Statement on Form S-8 is being filed to register the offer and sale of an additional 6,750,000 shares of Common Stock, \$0.01 par value per share (the "Common Stock"), of Vertex Pharmaceuticals Incorporated (the "Registrant") to be issued under the Amended and Restated 2013 Stock and Option Plan (the "2013 Plan") of the Registrant. In accordance with General Instruction E to Form S-8, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8 filed by the Registrant on May 21, 2013 (File No. 333-188737), relating to the Registrant's 2013 Plan, except for Item 8, Exhibits, with respect to which the Exhibit Index immediately preceding the exhibits attached hereto is incorporated herein by reference.

---



	<b>Signature</b>	<b>Title</b>	<b>Date</b>
By:	<u>/s/ JEFFREY M. LEIDEN</u> Jeffrey M. Leiden	Chairman, Chief Executive Officer and President (Principal Executive Officer)	July 28, 2017
By:	<u>/s/ IAN F. SMITH</u> Ian F. Smith	Executive Vice President, Chief Operating Officer and Chief Financial Officer (Principal Financial Officer)	July 28, 2017
By:	<u>/s/ PAUL M. SILVA</u> Paul M. Silva	Senior Vice President and Corporate Controller (Principal Accounting Officer)	July 28, 2017
By:	<u>/s/ SANGEETA N. BHATIA</u> Sangeeta N. Bhatia	Director	July 28, 2017
By:	<u>/s/ ALAN GARBER</u> Alan Garber	Director	July 28, 2017
By:	<u>/s/ TERRENCE C. KEARNEY</u> Terrence C. Kearney	Director	July 28, 2017
By:	<u>Yuchun Lee</u>	Director	
By:	<u>/s/ MARGARET G. MCGLYNN</u> Margaret G. McGlynn	Director	July 28, 2017
By:	<u>/s/ BRUCE I. SACHS</u> Bruce I. Sachs	Director	July 28, 2017
By:	<u>/s/ ELAINE S. ULLIAN</u> Elaine S. Ullian	Director	July 28, 2017
By:	<u>/s/ WILLIAM D. YOUNG</u> William D. Young	Director	July 28, 2017

---

**VERTEX PHARMACEUTICALS INCORPORATED**  
**INDEX TO EXHIBITS FILED WITH**  
**FORM S-8 REGISTRATION STATEMENT**

Exhibit Number	Exhibit Description	Filed with this Registration Statement	Incorporated by Reference herein from—Form or Schedule	Filing Date/ Period Covered	SEC File/ Reg. Number
4.1	Restated Articles of Organization of Vertex Pharmaceuticals Incorporated, as amended.		10-Q (Exhibit 3.1)	July 28, 2017	000-19319
4.2	Amended and Restated By-laws of Vertex Pharmaceuticals Incorporated, as subsequently amended on April 26, 2016 and June 8, 2017.		10-Q (Exhibit 3.2)	July 28, 2017	000-19319
4.3	Specimen stock certificate.		S-1 (Exhibit 4.1)	July 18, 1991	33-40966
5.1	Opinion of counsel as to the legality of the shares being registered.	X			
23.1	Consent of Ernst & Young LLP.	X			
23.2	Consent of counsel (included as part of Exhibit 5.1).	X			
24.1	Power of Attorney to file future amendments (set forth on signature page of this Registration Statement).	X			
99.1	Vertex Pharmaceuticals Incorporated Amended and Restated 2013 Stock and Option Plan.		DEF-14A (Appendix C)	April 28, 2017	000-19319

July 28, 2017

Vertex Pharmaceuticals Incorporated  
50 Northern Avenue  
Boston, Massachusetts 02210

Re: Vertex Pharmaceuticals Incorporated Amended and Restated 2013 Stock and Option Plan

Ladies and Gentlemen:

I have assisted in the preparation of the Registration Statement on Form S-8 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to an aggregate of 6,750,000 shares of common stock, \$0.01 par value per share (the "Shares"), of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the "Company"), issuable under the Company's Amended and Restated 2013 Stock and Option Plan (the "Plan").

I have examined the Articles of Organization and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to my satisfaction, of all pertinent records of the meetings of the directors and shareholders of the Company, the Registration Statement and such other documents relating to the Company as I have deemed material for the purposes of this opinion.

In my examination of the foregoing documents, I have assumed the genuineness of all signatures, the authenticity of all documents submitted to me as originals, the conformity to original documents of all documents submitted to me as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

I express no opinion herein as to the laws of any state or jurisdiction other than the state laws of The Commonwealth of Massachusetts and the federal laws of the United States of America. It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

Please note I am opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. I assume no obligation to revise or supplement this opinion should the present laws, or the interpretation thereof, be changed in respect of any circumstances or events that occur subsequent to the date hereof.

Based on the foregoing, I am of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plan, the Shares will be validly issued, fully paid and nonassessable.

I hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, I do not hereby admit that I am in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

/s/ Michael J. LaCascia

Michael J. LaCascia  
Senior Vice President, General Counsel and Corporate Secretary



**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Amended and Restated 2013 Stock and Option Plan of Vertex Pharmaceuticals Incorporated of our reports dated February 23, 2017, with respect to the consolidated financial statements of Vertex Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Vertex Pharmaceuticals Incorporated included in its Annual Report (Form 10-K) for the year ended December 31, 2016, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts  
July 28, 2017